GLP-1 receptor agonist

Comparative Effectiveness of Empagliflozin in the US

Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3

GLP-1 RA on Liver OMICS in MASLD

Impact GLP-1 Agonists Following Bariatric

Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS

Comparison of Body Composition Changes With Weight Loss Interventions

Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM

Pelvic Floor Disorder Symptoms in Women Seeking Weight Loss Therapy

Effect of GLP-1 Receptor Agonists on Trabecular Bone Score

Impact of GLP-1 Receptor Agonists on Patients With IPMN

Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes

Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity

Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease

Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes